Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive ...
Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration ...
Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye ...
Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab ...
The phase 2 EVITA trial (NCT03682029) was the first double-blind, randomized, placebo-controlled study of oral vitamin C in ...
Industry payments to oncologists were associated with increased use of the promoted cancer treatment, regardless of whether ...
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute rejects the idea that a TP53 co-mutation points toward chemotherapy ...
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated ...
With bispecifics, that’s extraordinarily rare. The incidence of ICANS with bispecifics is on the order of 5% or less, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results